Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2016

Open Access 01-07-2016 | Review

COPD immunopathology

Authors: Gaetano Caramori, Paolo Casolari, Adam Barczyk, Andrew L. Durham, Antonino Di Stefano, Ian Adcock

Published in: Seminars in Immunopathology | Issue 4/2016

Login to get access

Abstract

The immunopathology of chronic obstructive pulmonary disease (COPD) is based on the innate and adaptive inflammatory immune responses to the chronic inhalation of cigarette smoking. In the last quarter of the century, the analysis of specimens obtained from the lower airways of COPD patients compared with those from a control group of age-matched smokers with normal lung function has provided novel insights on the potential pathogenetic role of the different cells of the innate and acquired immune responses and their pro/anti-inflammatory mediators and intracellular signalling pathways, contributing to a better knowledge of the immunopathology of COPD both during its stable phase and during its exacerbations. This also has provided a scientific rationale for new drugs discovery and targeting to the lower airways. This review summarises and discusses the immunopathology of COPD patients, of different severity, compared with control smokers with normal lung function.
Literature
1.
Global Initiative for Chronic Obstructive Lung Disease (2016). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.​goldcopd.​org (Updated 2016)
2.
Gnatiuc L, Caramori G (2014) COPD in nonsmokers: the biomass hypothesis—to be or not to be? Eur Respir J 44:8–10PubMedCrossRef
3.
4.
Silverman EK, Sandhaus RA (2009) Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 360:2749–2757PubMedCrossRef
5.
Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J, Wardlaw AJ, Pavord ID (2002) Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 166:1078–1083PubMedCrossRef
6.
Rivera RM, Cosio MG, Ghezzo H, Salazar M, Pérez-Padilla R (2008) Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis 12:972–977PubMed
7.
Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33:1165–1185PubMedCrossRef
8.
Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709–721PubMedCrossRef
9.
Van Brabandt H, Cauberghs M, Verbeken E, Moerman P, Lauweryns JM, Van de Woestijne KP (1983) Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 55:1733–1742PubMed
10.
11.
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653PubMedCrossRef
12.
Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M (2006) Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:1309–1315PubMedCrossRef
13.
14.
Scherrer M (1961) Asthma, chronic bronchitis, and pulmonary emphysema. Ciba Symp 9:227–237PubMed
15.
Barnes PJ (2014) Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 35:71–86PubMedCrossRef
16.
Postma DS, Reddel HK, ten Hacken NH, van den Berge M (2014) Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med 35:143–156PubMedCrossRef
17.
Caramori G, Casolari P, Giuffrè S, Barczyk A, Adcock I, Papi A (2011) COPD pathology in the small airways. Panminerva Med 53:51–70PubMed
18.
Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4:435–459PubMedCrossRef
19.
D’Anna SE, Asnaghi R, Caramori G, Appendini L, Rizzo M, Cavallaro C, Marino G, Cappello F, Balbi B, Di Stefano A (2012) High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. Respiration 83:383–390PubMedCrossRef
20.
Galbán CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, Galbán S, Rehemtulla A, Kazerooni EA, Martinez FJ, Ross BD (2012) Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18:1711–1715PubMedPubMedCentralCrossRef
21.
McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, Paré PD, Sin DD, Pierce RA, Woods JC, McWilliams AM, Mayo JR, Lam SC, Cooper JD, Hogg JC (2011) Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365:1567–1575PubMedPubMedCentralCrossRef
22.
Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F, Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B (2014) Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 69:516–524PubMedPubMedCentralCrossRef
23.
Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, Maestrelli P, Cavallesco G, Papi A, Fabbri LM (2000) Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and airflow limitation. Am J Respir Crit Care Med 161:1016–1021PubMedCrossRef
24.
25.
Tzanakis N, Chrysofakis G, Tsoumakidou M, Kyriakou D, Tsiligianni J, Bouros D, Siafakas NM (2004) Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med 98:57–65PubMedCrossRef
26.
Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, Siafakas NM (2004) Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 125:71–76PubMedCrossRef
27.
Di Stefano A, Caramori G, Oates T, Capelli A, Lusuardi M, Gnemmi I, Ioli F, Chung KF, Donner CF, Barnes PJ, Adcock IM (2002) Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 20:556–563PubMedCrossRef
28.
Di Stefano A, Capelli A, Lusuardi M, Caramori G, Balbo P, Ioli F, Sacco S, Gnemmi I, Brun P, Adcock IM, Balbi B, Barnes PJ, Chung KF, Donner CF (2001) Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy 31:893–902PubMedCrossRef
29.
Costabel U, Guzman J (1992) Effect of smoking on bronchoalveolar lavage constituents. Eur Respir J 5:776–779PubMed
30.
Siena L, Gjomarkaj M, Elliot J, Pace E, Bruno A, Baraldo S, Saetta M, Bonsignore MR, James A (2011) Reduced apoptosis of CD8+ T-lymphocytes in the airways of smokers with mild/moderate COPD. Respir Med 105:1491–1500PubMedCrossRef
31.
Barceló B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agustí AG (2008) Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 31:555–562PubMedCrossRef
32.
Cosio MG (2004) Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur Respir J 24:3–5PubMedCrossRef
33.
Zhu J, Majumdar S, Qiu Y, Ansari T, Oliva A, Kips JC, Pauwels RA, De Rose V, Jeffery PK (2001) Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8+ cells. Am J Respir Crit Care Med 164:2220–2228PubMedCrossRef
34.
Halwani R, Al-Muhsen S, Hamid Q (2013) T helper 17 cells in airway diseases: from laboratory bench to bedside. Chest 143:494–501PubMedCrossRef
35.
Brusselle G, Bracke K (2014) Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc 11(Suppl 5):S322–S328PubMedCrossRef
36.
Vanaudenaerde BM, Verleden SE, Vos R, De Vleeschauwer SI, Willems-Widyastuti A, Geenens R, Van Raemdonck DE, Dupont LJ, Verbeken EK, Meyts I (2011) Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 183:977–986PubMedCrossRef
37.
Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ (2013) Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax 68:330–337PubMedCrossRef
38.
Chang Y, Al-Alwan L, Alshakfa S, Audusseau S, Mogas AK, Chouiali F, Nair P, Baglole CJ, Hamid Q, Eidelman DH (2014) Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD. Respir Res 15:145PubMedPubMedCentralCrossRef
39.
Di Stefano A, Caramori G, Gnemmi I, Contoli M, Vicari C, Capelli A, Magno F, D’Anna SE, Zanini A, Brun P, Casolari P, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B (2009) T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157:316–324PubMedPubMedCentralCrossRef
40.
Eustace A, Smyth LJ, Mitchell L, Williamson K, Plumb J, Singh D (2011) Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. Chest 139:1089–1100PubMedCrossRef
41.
Roos AB, Sandén C, Mori M, Bjermer L, Stampfli MR, Erjefält JS (2015) IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med 191:1232–1241PubMedCrossRef
42.
Zhang MQ, Wan Y, Jin Y, Xin JB, Zhang JC, Xiong XZ, Chen L, Chen G (2014) Cigarette smoking promotes inflammation in patients with COPD by affecting the polarization and survival of Th/Tregs through up-regulation of muscarinic receptor 3 and 5 expression. PLoS One 9, e112350PubMedPubMedCentralCrossRef
43.
Urboniene D, Babusyte A, Lötvall J, Sakalauskas R, Sitkauskiene B (2013) Distribution of γδ and other T-lymphocyte subsets in patients with chronic obstructive pulmonary disease and asthma. Respir Med 107:413–4723PubMedCrossRef
44.
Freeman CM, McCubbrey AL, Crudgington S, Nelson J, Martinez FJ, Han MK, Washko GR Jr, Chensue SW, Arenberg DA, Meldrum CA, McCloskey L, Curtis JL (2014) Basal gene expression by lung CD4+ T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. PLoS One 9, e96421PubMedPubMedCentralCrossRef
45.
Cosio MG, Saetta M, Agusti A (2009) Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 360:2445–2454PubMedCrossRef
46.
Bhat TA, Panzica L, Kalathil SG, Thanavala Y (2015) Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 12(Suppl 2):S169–S175PubMedPubMedCentral
47.
Isajevs S, Taivans I, Strazda G, Kopeika U, Bukovskis M, Gordjusina V, Kratovska A (2009) Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J 33:61–67PubMedCrossRef
48.
Hou J, Sun Y, Hao Y, Zhuo J, Liu X, Bai P, Han J, Zheng X, Zeng H (2013) Imbalance between subpopulations of regulatory T cells in COPD. Thorax 68:1131–1139PubMedCrossRef
49.
Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, Thanavala Y (2014) T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 190:40–50PubMedPubMedCentralCrossRef
50.
Li H, Liu Q, Jiang Y, Zhang Y, Zhang Y, Xiao W (2015) Disruption of th17/treg balance in the sputum of patients with chronic obstructive pulmonary disease. Am J Med Sci 349:392–397PubMedCrossRef
51.
Cappello F, Caramori G, Campanella C, Vicari C, Gnemmi I, Zanini A, Spanevello A, Capelli A, La Rocca G, Anzalone R, Bucchieri F, D’Anna SE, Ricciardolo FL, Brun P, Balbi B, Carone M, Zummo G, Conway de Macario E, Macario AJ, Di Stefano A (2011) Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis. PLoS One 6, e28200PubMedPubMedCentralCrossRef
52.
Pridgeon C, Bugeon L, Donnelly L, Straschil U, Tudhope SJ, Fenwick P, Lamb JR, Barnes PJ, Dallman MJ (2011) Regulation of IL-17 in chronic inflammation in the human lung. Clin Sci (Lond) 120:515–524CrossRef
53.
Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F (2007) Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13:567–569PubMedCrossRef
54.
Kirkham PA, Caramori G, Casolari P, Papi AA, Edwards M, Shamji B, Triantaphyllopoulos K, Hussain F, Pinart M, Khan Y, Heinemann L, Stevens L, Yeadon M, Barnes PJ, Chung KF, Adcock IM (2011) Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184:796–802PubMedPubMedCentralCrossRef
55.
Olloquequi J, Ferrer J, Montes JF, Rodríguez E, Montero MA, García-Valero J (2010) Differential lymphocyte infiltration in small airways and lung parenchyma in COPD patients. Respir Med 104:1310–1318PubMedCrossRef
56.
Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W (2009) Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 34:219–230PubMedCrossRef
57.
van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, van den Berg A, Timens W, Kerstjens HA (2006) Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 173:751–758PubMedCrossRef
58.
Polverino F, Baraldo S, Bazzan E, Agostini S, Turato G, Lunardi F, Balestro E, Damin M, Papi A, Maestrelli P, Calabrese F, Saetta M (2010) A novel insight into adaptive immunity in COPD: B cell activating factor belonging to the TNF family (BAFF). Am J Respir Crit Care Med 182:1011–1019PubMedCrossRef
59.
Polverino F, Cosio BG, Pons J, Laucho-Contreras M, Tejera P, Iglesias A, Rios A, Jahn A, Sauleda J, Divo M, Pinto-Plata V, Sholl L, Rosas IO, Agustí A, Celli BR, Owen CA (2015) B cell-activating factor. An orchestrator of lymphoid follicles in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192:695–705PubMedPubMedCentralCrossRef
60.
Seys LJ, Verhamme FM, Schinwald A, Hammad H, Cunoosamy DM, Bantsimba-Malanda C, Sabirsh A, McCall E, Flavell L, Herbst R, Provoost S, Lambrecht BN, Joos GF, Brusselle GG, Bracke KR (2015) Role of B cell-activating factor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192:706–718PubMedCrossRef
61.
Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, Tal-Singer R, Miller B, Rodriguez-Roisin R, Spira A, Kalko SG, Agusti A (2016) Network analysis of lung transcriptomics reveals a distinct B cell signature in emphysema. Am J Respir Crit Care Med
62.
Hogg JC, Chu FSF, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, Sharafkhaneh A, Luketich JD, Coxson HO, Elliott WM, Sciurba FC (2007) Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 176:454–459PubMedPubMedCentralCrossRef
63.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789PubMedCrossRef
64.
Focosi D, Bestagno M, Burrone O, Petrini M (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87:107–116PubMedCrossRef
65.
Birch J, Anderson RK, Correia-Melo C, Jurk D, Hewitt G, Marques FM, Green NJ, Moisey E, Birrell MA, Belvisi MG, Black F, Taylor JJ, Fisher AJ, De Soyza A, Passos JF (2015) DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 309:L1124–L1137PubMedPubMedCentral
66.
Olloquequi J, Montes JF, Prats A, Rodríguez E, Montero MA, García-Valero J, Ferrer J (2011) Significant increase of CD57+ cells in pulmonary lymphoid follicles of COPD patients. Eur Respir J 37:289–298PubMedCrossRef
67.
Hiemstra PS (2013) Altered macrophage function in chronic obstructive pulmonary disease. Ann Am Thorac Soc 10(Suppl):S180–S185PubMedCrossRef
68.
Chana KK, Fenwick PS, Nicholson AG, Barnes PJ, Donnelly LE (2014) Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 133:207–216PubMedCrossRef
69.
Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL (2014) Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 40:274–288PubMedPubMedCentralCrossRef
70.
Kaku Y, Imaoka H, Morimatsu Y, Komohara Y, Ohnishi K, Oda H, Takenaka S, Matsuoka M, Kawayama T, Takeya M, Hoshino T (2014) Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS One 9, e87400PubMedPubMedCentralCrossRef
71.
Brusselle GG, Joos GF, Bracke KR (2011) New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378:1015–1026PubMedCrossRef
72.
Tsoumakidou M, Bouloukaki I, Koutala H, Kouvidi K, Mitrouska I, Zakynthinos S, Tzanakis N, Jeffery PK, Siafakas NM (2009) Decreased sputum mature dendritic cells in healthy smokers and patients with chronic obstructive pulmonary disease. Int Arch Allergy Immunol 150:389–397PubMedCrossRef
73.
Rogers AV, Adelroth E, Hattotuwa K, Dewar A, Jeffery PK (2008) Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study. Thorax 63:108–114PubMedCrossRef
74.
Zanini A, Spanevello A, Baraldo S, Majori M, Della Patrona S, Gumiero F, Aiello M, Olivieri D, Saetta M, Chetta A (2014) Decreased maturation of dendritic cells in the central airways of COPD patients is associated with VEGF, TGF-β and vascularity. Respiration 87:234–242PubMedCrossRef
75.
Stoll P, Heinz AS, Bratke K, Bier A, Garbe K, Kuepper M, Virchow JC, Lommatzsch M (2014) Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD. Respir Res 15:48PubMedPubMedCentralCrossRef
76.
Tsoumakidou M, Koutsopoulos AV, Tzanakis N, Dambaki K, Tzortzaki E, Zakynthinos S, Jeffery PK, Siafakas NM (2009) Decreased small airway and alveolar CD83+ dendritic cells in COPD. Chest 136:726–733PubMedCrossRef
77.
Liao SX, Ding T, Rao XM, Sun DS, Sun PP, Wang YJ, Fu DD, Liu XL, Ou-Yang Y (2015) Cigarette smoke affects dendritic cell maturation in the small airways of patients with chronic obstructive pulmonary disease. Mol Med Rep 11:219–225PubMed
78.
Demedts IK, Bracke KR, Van Pottelberge G, Testelmans D, Verleden GM, Vermassen FE, Joos GF, Brusselle GG (2007) Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:998–1005PubMedCrossRef
79.
Vassallo R, Walters PR, Lamont J, Kottom TJ, Yi ES, Limper AH (2010) Cigarette smoke promotes dendritic cell accumulation in COPD; a lung tissue research consortium study. Respir Res 11:45–57PubMedPubMedCentralCrossRef
80.
Van Pottelberge GR, Bracke KR, Demedts IK, De Rijck K, Reinartz SM, van Drunen CM, Verleden GM, Vermassen FE, Joos GF, Brusselle GG (2010) Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respir Res 11:35PubMedPubMedCentralCrossRef
81.
Balzano G, Stefanelli F, Iorio C, De Felice A, Melillo EM, Martucci M, Melillo G (1999) Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med 160:1486–1492PubMedCrossRef
82.
Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerkin M, Rennard SI (1989) Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 140:1527–1537PubMedCrossRef
83.
Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM (1997) Chronic obstructive pulmonary disease: role of bronchial mast cells and macrophages. Am J Pathol 151:1785–1790PubMedPubMedCentral
84.
Baraldo S, Turato G, Badin C, Bazzan E, Beghé B, Zuin R, Calabrese F, Casoni G, Maestrelli P, Papi A, Fabbri LM, Saetta M (2004) Neutrophilic infiltration within the airway smooth muscle in patients with COPD. Thorax 59:308–312PubMedPubMedCentralCrossRef
85.
Tsoumakidou M, Tsiligianni I, Tzanakis N (2011) Mechanisms of altered cell immunity and cytotoxicity in COPD. Curr Drug Targets 12:450–459PubMedCrossRef
86.
Upham JW, Stick SM (2006) Interactions between airway epithelial cells and dendritic cells: implications for the regulation of airway inflammation. Curr Drug Targets 7:541–545PubMedCrossRef
87.
Schulz C, Wolf K, Harth M, Kratzel K, Kunz-Schughart L, Pfeifer M (2003) Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 70:254–261PubMedCrossRef
88.
Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, Nakayama K, Yanai M, Numazaki Y, Sasaki H (2001) Bafilomycin A1 inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1. Am J Physiol Lung Cell Mol Physiol 280:L1115–L1127PubMed
89.
90.
de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P (2007) Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 175:32–39PubMedCrossRef
91.
Caramori G, Casolari P, Di Gregorio C, Saetta M, Baraldo S, Boschetto P, Ito K, Fabbri LM, Barnes PJ, Adcock IM, Cavallesco G, Chung KF, Papi A (2009) MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology 55:321–331PubMedCrossRef
92.
Hovenberg HW, Davies JR, Carlstedt I (1996) Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 318(Pt 1):319–324PubMedPubMedCentralCrossRef
93.
Schulz BL, Sloane AJ, Robinson LJ, Sebastian LT, Glanville AR, Song Y, Verkman AS, Harry JL, Packer NH, Karlsson NG (2005) Mucin glycosylation changes in cystic fibrosis lung disease are not manifest in submucosal gland secretions. Biochem J 387(Pt 3):911–919PubMedPubMedCentralCrossRef
94.
Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 86:245–278PubMedCrossRef
95.
Hovenberg HW, Davies JR, Herrmann A, Lindén CJ, Carlstedt I (1996) MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj J 13:839–847PubMedCrossRef
96.
Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ (2002) Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 361(Pt 3):537–546PubMedPubMedCentralCrossRef
97.
Kirkham S, Kolsum U, Rousseau K, Singh D, Vestbo J, Thornton DJ (2008) MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:1033–1039PubMedPubMedCentralCrossRef
98.
Innes AL, Woodruff PG, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV (2006) Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 130:1102–1108PubMedCrossRef
99.
O’Donnell RA, Richter A, Ward J, Angco G, Mehta A, Rousseau K, Swallow DM, Holgate ST, Djukanovic R, Davies DE, Wilson SJ (2004) Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 59:1032–1040PubMedPubMedCentralCrossRef
100.
Silvers GW, Maisel JC, Petty TL, Mitchell RS (1973) Reduction in peripheral airway resistance in excised emphysematous lungs. Chest 63(Suppl):32S–33SCrossRef
101.
Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Cavallesco G, Chung KF, Papi A (2004) Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology 45:477–484PubMedCrossRef
102.
Di Comite G, Grazia Sabbadini M, Corti A, Rovere-Querini P, Manfredi AA (2007) Conversation galante: how the immune and the neuroendocrine systems talk to each other. Autoimmun Rev 7:23–29PubMedCrossRef
103.
Profita M, Albano GD, Riccobono L, Di Sano C, Montalbano AM, Gagliardo R, Anzalone G, Bonanno A, Pieper MP, Gjomarkaj M (2014) Increased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patients. Immunobiology 219:392–401PubMedCrossRef
104.
Gu X, Karp PH, Brody SL, Pierce RA, Welsh MJ, Holtzman MJ, Ben-Shahar Y (2014) Chemosensory functions for pulmonary neuroendocrine cells. Am J Respir Cell Mol Biol 50:637–646PubMedPubMedCentralCrossRef
105.
Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, Corcione N, Marsico SA, Guerra G (2010) Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents 24:425–432PubMed
106.
Lucchini RE, Facchini F, Turato G, Saetta M, Caramori G, Ciaccia A, Maestrelli P, Springall DR, Polak JM, Fabbri L, Mapp CE (1997) Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med 156:1963–68PubMedCrossRef
107.
Miotto D, Boschetto P, Bononi I, Zeni E, Cavallesco G, Fabbri LM, Mapp CE (2004) Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J 24:958–963PubMedCrossRef
108.
Calabrese F, Giacometti C, Beghe B, Rea F, Loy M, Zuin R, Marulli G, Baraldo S, Saetta M, Valente M (2005) Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema. Respir Res 6:14PubMedPubMedCentralCrossRef
109.
Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF (2001) Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 163:737–744PubMedCrossRef
110.
111.
Suzuki M, Betsuyaku T, Nagai K, Fuke S, Nasuhara Y, Kaga K, Kondo S, Hamamura I, Hata J, Takahashi H, Nishimura M (2008) Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. Inhal Toxicol 20:349–359PubMedCrossRef
112.
Marwick JA, Stevenson CS, Giddings J, MacNee W, Butler K, Rahman I, Kirkham PA (2006) Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Am J Physiol Lung Cell Mol Physiol 290:L897–L908PubMedCrossRef
113.
Santos S, Peinado VI, Ramirez J, Morales-Blanhir J, Bastos R, Roca J, Rodriguez-Roisin R, Barbera JA (2003) Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1250–1256PubMedCrossRef
114.
Barberà JA, Blanco I (2009) Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 69:1153–1171PubMedCrossRef
115.
Zakynthinos E, Daniil Z, Papanikolaou J, Makris D (2011) Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets 12:501–513PubMedCrossRef
116.
Rowan SC, Keane MP, Gaine S, McLoughlin P (2016) Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. Lancet Respir Med 4(3):225–236PubMedCrossRef
117.
Kew KM, Seniukovich A (2014) Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3, CD010115
118.
Liapikou A, Toumbis M, Torres A (2015) Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opin Drug Saf 14:1237–1247PubMedCrossRef
119.
Jen R, Rennard SI, Sin DD (2012) Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 7:587–595PubMedPubMedCentral
120.
Ozol D, Aysan T, Solak ZA, Mogulkoc N, Veral A, Sebik F (2005) The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 99:1494–1500PubMedCrossRef
121.
Verhoeven GT, Garrelds IM, Hoogsteden HC, Zijlstra FJ (2001) Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediat Inflamm 10:21–26CrossRef
122.
Keatings VM, Barnes PJ (1997) Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 155:449–453PubMedCrossRef
123.
Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saeatta M (2006) Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:6–14PubMedCrossRef
124.
Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q (2007) Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 62:938–943PubMedPubMedCentralCrossRef
125.
Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ (2009) Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151:517–527PubMedCrossRef
126.
Lommatzsch M, Kraeft U, Troebs L, Garbe K, Bier A, Stoll P, Klammt S, Kuepper M, Bratke K, Virchow JC (2013) Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial. Respir Res 14:114PubMedPubMedCentralCrossRef
127.
128.
129.
Caramori G, Di Stefano A, Casolari P, Kirkham PA, Padovani A, Chung KF, Papi A, Adcock IM (2013) Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease. Curr Med Chem 20:4317–4349PubMedCrossRef
130.
Caramori G, Adcock IM, Di Stefano A, Chung KF (2014) Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 9:397–412PubMedPubMedCentral
131.
132.
Papi A, Luppi F, Franco F, Fabbri LM (2006) Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:245–251PubMedCrossRef
133.
134.
135.
Ricciardolo FL, Caramori G, Ito K, Capelli A, Brun P, Abatangelo G, Papi A, Chung KF, Adcock I, Barnes PJ, Donner CF, Rossi A, Di Stefano A (2005) Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol 116:1028–1035PubMedCrossRef
136.
Wiegman CH, Michaeloudes C, Haji G, Narang P, Clarke CJ, Russell KE, Bao W, Pavlidis S, Barnes PJ, Kanerva J, Bittner A, Rao N, Murphy MP, Kirkham PA, Chung KF, Adcock IM, COPDMAP (2015) Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 136:769–780PubMedPubMedCentralCrossRef
137.
Gershon AS, Warner L, Cascagnette P, Victor JC, To T (2011) Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 378:991–996PubMedCrossRef
138.
Makris D, Lazarou S, Alexandrakis M, Kourelis TV, Tzanakis N, Kyriakou D, Gourgoulianis KI (2008) Tc2 response at the onset of COPD exacerbations. Chest 134:483–488PubMedCrossRef
139.
Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM (2005) Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 99:572–579PubMedCrossRef
140.
Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK (2003) Biopsy neutrophilia, chemokine and receptor gene expression in severe exacerbations of COPD. Am J Respir Crit Care Med 168:968–975PubMedCrossRef
141.
Nagai A, West WW, Paul JL, Thurlbeck WM (1985) The National Institutes of Health Intermittent Positive-Pressure Breathing Trial: pathology studies. I. Interrelationship between morphologic lesions. Am Rev Respir Dis 132:937–945PubMed
142.
Nagai A, West WW, Thurlbeck WM (1985) The National Institutes of Health Intermittent Positive-Pressure Breathing Trial: pathology studies. II. Correlation between morphologic findings, clinical findings and evidence of expiratory air-flow obstruction. Am Rev Respir Dis 132:946–953PubMed
143.
Ritchie AI, Farne HA, Singanayagam A, Jackson DJ, Mallia P, Johnston SL (2015) Pathogenesis of viral infection in exacerbations of airway disease. Ann Am Thorac Soc 12(Suppl 2):S115–S132PubMed
144.
Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P (2016) The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 10(2):158–174PubMedCrossRef
145.
Sajjan US, Jia Y, Newcomb DC, Bentley JK, Lukacs NW, LiPuma JJ, Hershenson MB (2006) H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J 20:2121–2123PubMedCrossRef
146.
Marc MM, Korosec P, Kern I, Sok M, Ihan A, Kosnik M (2007) Lung tissue and tumour- infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD. Scand J Immunol 66:694–702PubMedCrossRef
147.
Domagala-Kulawik J, Maskey-Warzecowska M (2009) T-regulatory cells in COPD or tumour environment. Eur Respir J 34:284, author reply 285–286 PubMedCrossRef
148.
Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pachéco Y, Lebecque S (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178:2763–2769PubMedCrossRef
149.
de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, van Krieken JH (1998) Transforming growth factor β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:1951–1957PubMedCrossRef
Metadata
Title
COPD immunopathology
Authors
Gaetano Caramori
Paolo Casolari
Adam Barczyk
Andrew L. Durham
Antonino Di Stefano
Ian Adcock
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-016-0561-5

Other articles of this Issue 4/2016

Seminars in Immunopathology 4/2016 Go to the issue

Review

The IL-1 cytokine family and its role in inflammation and fibrosis in the lung

Introduction

Immunopathology of lung diseases: introduction for the special issue

Review

Dendritic cells in lung immunopathology

Review

The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation

Review

The host immune response in respiratory virus infection: balancing virus clearance and immunopathology

Review Article

Type 2 innate lymphoid cells: at the cross-roads in allergic asthma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits